ASX-Dividend-Report-Banner

/C O R R E C T I O N -- Menarini Silicon Biosystems/

July 03, 2024 05:24 AM AEST | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 /C O R R E C T I O N -- Menarini Silicon Biosystems/
Image source: Kalkine Media

In the news release, Menarini's cell based non-invasive prenatal technology demonstrates high resolution detection of fetal genomic abnormalities from a simple maternal blood draw, issued 02-Jul-2024 by Menarini Silicon Biosystems over PR Newswire, we are advised by the company that the subheadline, second sentence and the second paragraph, second sentence should read "400Kb" rather than "600Kb" as originally issued inadvertently. The complete, corrected release follows:

Menarini's cell based non-invasive prenatal technology demonstrates high resolution detection of fetal genomic abnormalities from a simple maternal blood draw

Data presented at the 2024 FMF (Fetal Medicine Foundation) World Congress in Lisbon, Portugal shows the potential for an automated system to deliver genomic profiles of fetal cells that is highly concordant with the genomic analysis obtained from invasive procedures. Results of a large clinical validation study show that Menarini Silicon Biosystems' fetal cell based noninvasive prenatal screening (NIPT) technology can accurately detect both fetal genome-wide pathogenic copy number variants greater than 400Kb in size and the commonly screened trisomy conditions.

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., July 3, 2024 /PRNewswire/ --The Reproductive Precision Medicine Unit of Menarini Silicon Biosystems (MSB) presented last week, at the 21st World Congress of the Fetal Medicine Foundation meeting in Lisbon, Portugal, results of a large multicenter study describing their next generation non-invasive prenatal testing technology using fetal cells isolated from maternal blood. The genomic analysis of these fetal cells showed a high concordance with the analysis of fetal cells obtained from invasive diagnostic procedures. Moreover, MSB's cell-based test, under development, demonstrated its potential validity for screening genomic conditions not easily found with currently available, state of the art, non-invasive screening technologies based on cell-free DNA (cfDNA) analysis.

This large study, which enrolled over 1,000 women, was centered on isolating individual fetal (trophoblast) cells from maternal blood and analyzing them for both common trisomic conditions and genome-wide microdeletions and microduplications, called pathogenic copy number variants (pCNVs), that account for significant perinatal morbidity and mortality. The results presented showed that MSB's fetal cell based NIPT could deliver information beyond core "common" trisomies detected by standard non-invasive cfDNA analysis, as well as detect with a high level of accuracy and granularity genome-wide microdeletions and microduplications down to a size of at least 400Kb. The cell-based test was compared with chromosomal microarray analysis (CMA) and karyotype from chorionic villus sampling (CVS) or amniocentesis, the clinical gold - standard fetal diagnostic methodologies to detect genomic chromosomal abnormalities in the prenatal setting.

According to Professor Jon Hyett, Head of Maternal and Fetal Medicine at Liverpool Hospital and Professor of Obstetrics and Gynaecology at Western Sydney University, who looks after pregnancies that have a high risk of complication – either for the mother, or for the fetus: "This data is exciting because it shows the potential to deliver clinically relevant and actionable information about fetal genomic abnormalities  at higher resolution and accuracy than existing screening tests and at an early gestational age when almost no pCNVs are currently detected." Menarini's new study thereby opens the door to a whole new paradigm in prenatal screening.

For Thomas Musci, MD, Chief Medical Officer, Head of Menarini Silicon Biosystems' Reproductive Precision Medicine Business Unit, who presented the results of the study, "Isolating intact fetal cells from maternal blood for prenatal screening has  long been perceived as an extremely challenging goal. Our highly automated system for the isolation and singlecell analysis of circulating extravillous trophoblasts (cEVTs) supports the feasibility of a cellbased NIPT for fetal genomic profiling that can lead to more informed decision-making at all levels."

Menarini has been actively investing to advance single cell analysis and sequencing in the field of reproductive care. For Fabio Piazzalunga, President of Menarini Silicon Biosystems, "The results of this study, which confirmed the potential ability of our cell based NIPT to identify fetal abnormalities with high sensitivity, accuracy, and specificity, show the potential of Menarini to significantly impact women's health. Our continuous commitment and efforts to advance our scientific findings in this field aim to provide, in the future, a potentially revolutionary solution that brings more information to women and their doctors". These new activities fully support the company's vision to become a leader in minimally invasive cell-based applications that can allow for easier, faster, and more precise diagnostic and therapeutic approaches in multiple therapeutic areas.

About Menarini Silicon Biosystems (MSB)

MSB offers unique rare cell technologies and solutions that provide clinical researchers with access to unparalleled resolution in the study of cells and their molecular characterization.

Menarini Silicon Biosystems, based in Castel Maggiore (Bologna, Italy), and Huntingdon Valley, PA., U.S., is a wholly owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology and diagnostics company headquartered in Florence, Italy, with more than 17,000 employees in 140 countries.

Contact:
PAVY Consulting
Linda PAVY
[email protected] 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.